Vertex Pharmaceuticals Reports Earnings on Feb. 12

Investors watch for updates on the launch of new cystic fibrosis drug Alyftrek and pain therapy Journavx

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Vertex Pharmaceuticals, known for its cystic fibrosis (CF) treatments, is set to report earnings on February 12. The company's stock has underperformed the market over the past year, rising less than 2%. Investors will be closely watching the progress of Alyftrek, Vertex's newest CF therapy, as well as the ongoing launch of its non-opioid pain therapy Journavx. The company is expected to report quarterly revenue of $3.17 billion and earnings per share of $5.07.

Why it matters

Vertex's ability to expand its CF franchise and use that revenue to develop therapies in other areas is crucial for the company's long-term growth. The performance of Alyftrek and Journavx will be key indicators of Vertex's future potential.

The details

Vertex reported third-quarter earnings in November 2025, with revenue up 11% year-over-year to $3.08 billion. However, earnings per share rose only 4.7% to $4.20 as increased research and development expenses offset some of the revenue growth. Investors were disappointed by underwhelming sales of some of Vertex's newer therapies. Alyftrek, Vertex's newest CF therapy, had sales of $247 million in the third quarter, below analysts' expectations. The company's non-opioid pain therapy Journavx also had disappointing sales of $33 million in the quarter.

  • Vertex is scheduled to report earnings on February 12, 2026.
  • In the third quarter of 2025, Vertex reported revenue of $3.08 billion, up 11% year-over-year.

The players

Vertex Pharmaceuticals

A biotech company known for its cystic fibrosis (CF) treatments, including its newest therapy Alyftrek.

Alyftrek

Vertex's newest CF therapy, which is considered the best CFTR modulator among the company's therapies and is taken as a pill only once a day, unlike Vertex's previous lead CF therapy Trikafta.

Journavx

Vertex's non-opioid pain therapy, which had disappointing sales of $33 million in the third quarter of 2025.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Vertex's earnings report on February 12 to see if Alyftrek and Journavx sales show a stronger uptick.

The takeaway

Vertex's performance in the fourth quarter, particularly the sales of its newer therapies Alyftrek and Journavx, will be a key indicator of the company's future potential as it looks to expand beyond its core cystic fibrosis business.